중앙백신
Financials
Valuation Metrics
중앙백신's Market Cap is ₩825B. At end of 2025 it was ₩907B. Ranked #1345 of 2,410 in KR market (top 56%), #748 of 1,631 on KOSDAQ (top 46%), #150 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 82.48B KRW | KR#1,345/2,410 Sec#150/231 |
| Revenue | 48.28B KRW | KR#1,810/2,410 Sec#126/231 |
| Net Income | 7.99B KRW | KR#1,039/2,410 Sec#64/231 |
| Total Assets | 125.52B KRW | KR#1,618/2,410 Sec#127/231 |
| Net Assets | 108.11B KRW | KR#1,354/2,410 Sec#106/231 |
| Employees | 187 | KR#1,146/2,410 Sec#95/231 |
| Value | ||
| P/E | 10.33x | KR#898/2,410 Sec#45/231 |
| P/B | 0.76x | KR#1,302/2,410 Sec#77/231 |
| PEG | 0.29x | KR#646/2,410 Sec#37/231 |
| P/S | 1.71x | KR#1,778/2,410 Sec#103/231 |
| EV/EBITDA | 10.91x | KR#709/2,410 Sec#35/231 |
| FCF Yield | 2.37% | KR#1,051/2,410 Sec#69/231 |
| Profitability | ||
| ROE | 7.39% | KR#852/2,410 Sec#60/231 |
| ROA | 6.36% | KR#587/2,410 Sec#47/231 |
| Op. Margin | 14.15% | KR#327/2,410 Sec#30/231 |
| Revenue Growth | 2.18% | KR#1,368/2,410 Sec#135/231 |
| Earnings Growth | 35.38% | KR#620/2,410 Sec#41/231 |
| Financial Health | ||
| Debt Ratio | 16.10% | KR#276/2,410 Sec#41/231 |
| Total Debt | 6.17B KRW | KR#1,738/2,410 Sec#165/231 |
| FCF | 1.95B KRW | KR#1,084/2,410 Sec#78/231 |
| Cash | 14.14B KRW | KR#1,477/2,410 Sec#120/231 |
| Current Ratio | 4.31x | KR#342/2,410 Sec#54/231 |
| Net Debt/EBITDA | -1.17x | KR#344/2,410 Sec#17/231 |
| Dividend | ||
| Div. Yield | 2.27% | KR#869/2,410 Sec#43/231 |
| Div. Growth | 17.65% | KR#478/2,410 Sec#26/231 |
| Performance | ||
| 1Y Return | -8.80% | KR#728/2,410 Sec#39/231 |
| 1M Return | -2.73% | KR#459/2,410 Sec#47/231 |
| From 52W High | -13.91% | KR#80/2,410 Sec#3/231 |
| 1Y MDD | -13.41% | KR#13/2,410 Sec#1/231 |
| Trading | ||
| Volume | 13,778 shares | KR#2,014/2,410 Sec#206/231 |
| Trading Value | 123.0M KRW | KR#1,708/2,410 Sec#182/231 |
| Foreign Own. | 2.53% | KR#1,442/2,410 Sec#135/231 |
| Per Share | ||
| EPS | 863 KRW | KR#783/2,410 Sec#55/231 |
| BPS | 11,679 KRW | KR#882/2,410 Sec#61/231 |
Company Info
Joongang Vaccine was established in 1968 as a private enterprise, converted to a corporation in 1994, and listed on KOSDAQ in 2003. Headquartered in Yuseong-gu, Daejeon, it manufactures about 80 types of animal vaccines for disease prevention, selling them to farms, distributors, and animal hospitals, and provides feed additive sales, rabies testing, disease diagnosis, and research services for biological products. With strengthened antibiotic regulations, the focus is shifting from treatment to prevention, increasing demand for animal vaccines, and the company is developing new markets in Southeast Asia, South America, and China.